Access
To read this story in full you will need to login or make a payment (see right).
Article
Nature 441, 475-482 (25 May 2006) | doi:10.1038/nature04703; Received 1 October 2005; Accepted 1 March 2006; Published online 5 April 2006
Open Innovation Challenges
-
Efficient Chromosome Doubling: Plant Cell Division
The Seeker is looking for an efficient chromosome doubling method in plants and in particular, metho...
-
Protect Enzyme from In Planta Degradation
A proposal for stable expression of an enzyme in corn seed is desired.
nature jobs
Developer - Variation (Bioinformatician)
- European Bioinformatics Institute (EBI)
- Cambridge CB10 1SD United Kingdom
Biochemical Pharmacologist
- Eisai London Research Laboratories Ltd
- Hatfield, United Kingdom
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Ömer H. Yilmaz1, Riccardo Valdez2, Brian K. Theisen2, Wei Guo3, David O. Ferguson2, Hong Wu3 & Sean J. Morrison1
- Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109-2216, USA
- Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109-2216, USA
- Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095-1735, USA
Correspondence to: Sean J. Morrison1 Correspondence and requests for materials should be addressed to S.J.M. (Email: seanjm@umich.edu).
Abstract
Recent advances have highlighted extensive phenotypic and functional similarities between normal stem cells and cancer stem cells. This raises the question of whether disease therapies can be developed that eliminate cancer stem cells without eliminating normal stem cells. Here we address this issue by conditionally deleting the Pten tumour suppressor gene in adult haematopoietic cells. This led to myeloproliferative disease within days and transplantable leukaemias within weeks. Pten deletion also promoted haematopoietic stem cell (HSC) proliferation. However, this led to HSC depletion via a cell-autonomous mechanism, preventing these cells from stably reconstituting irradiated mice. In contrast to leukaemia-initiating cells, HSCs were therefore unable to maintain themselves without Pten. These effects were mostly mediated by mTOR as they were inhibited by rapamycin. Rapamycin not only depleted leukaemia-initiating cells but also restored normal HSC function. Mechanistic differences between normal stem cells and cancer stem cells can thus be targeted to deplete cancer stem cells without damaging normal stem cells.
- Howard Hughes Medical Institute, Life Sciences Institute, Department of Internal Medicine, and Center for Stem Cell Biology, University of Michigan, Ann Arbor, Michigan 48109-2216, USA
- Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109-2216, USA
- Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095-1735, USA
Correspondence to: Sean J. Morrison1 Correspondence and requests for materials should be addressed to S.J.M. (Email: seanjm@umich.edu).
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
A GTP-binding adapter protein couples TRAIL receptors to apoptosis-inducing proteinsNature Immunology Article (01 Jun 2001)
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transferNature Immunology Article (01 Oct 2001)
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia preventionNature Letters to Editor (25 May 2006)
See all 70 matches for Research
